See more : Hi-Tech Pipes Limited (HITECH.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Rain Therapeutics Inc. (RAIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rain Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Storytel AB (publ) (STORY-B.ST) Income Statement Analysis – Financial Results
- C & C Constructions Limited (CANDC.NS) Income Statement Analysis – Financial Results
- Mudrick Capital Acquisition Corporation II (MUDS) Income Statement Analysis – Financial Results
- HF Company SA (HF.PA) Income Statement Analysis – Financial Results
- Camex Limited (CAMEXLTD.BO) Income Statement Analysis – Financial Results
Rain Therapeutics Inc. (RAIN)
About Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.40M | 40.77M | 15.37M | 7.29M |
| General & Administrative | 15.74M | 10.74M | 3.59M | 3.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.74M | 10.74M | 3.59M | 3.54M |
| Other Expenses | 0.00 | 1.00K | -2.02M | -251.00K |
| Operating Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Cost & Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Interest Income | 1.42M | 119.00K | 32.00K | 209.00K |
| Interest Expense | 0.00 | 0.00 | 135.00K | 32.00K |
| Depreciation & Amortization | 80.00K | 120.00K | -1.94M | -14.00K |
| EBITDA | -77.06M | -51.51M | -18.91M | -10.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -77.14M | -51.51M | -18.96M | -10.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 120.00K | -2.13M | -74.00K |
| Income Before Tax | -75.72M | -51.39M | -21.08M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00K | 2.00K | -1.89M | -219.00K |
| Net Income | -75.72M | -51.39M | -19.20M | -10.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.71 | -2.65 | -1.80 | -1.00 |
| EPS Diluted | -2.71 | -2.65 | -1.80 | -1.00 |
| Weighted Avg Shares Out | 27.99M | 19.41M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 27.99M | 19.41M | 10.66M | 10.66M |
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Rain Investors of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , Aug. 7, 2023 /PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between July 20, 2021 and...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAIN
NEW YORK , Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN). Such investors are advised to contact Robert S.
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RAIN
NEW YORK , Aug. 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the "Class...
RAIN SHAREHOLDER ALERT: Jakubowitz Law Reminds Rain Shareholders of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , Aug. 4, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN). To receive updates on the lawsuit, fill out the form:...
RAIN LAWSUIT ALERT: Levi & Korsinsky Notifies Rain Oncology Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Aug. 3, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rain...
RAIN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 12, 2023 in the Class Action Filed on Behalf of Rain Oncology Inc. Shareholders
NEW YORK , Aug. 1, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN) alleging that the Company violated federal securities laws. Class...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Rain Investors of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , July 31, 2023 /PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between July 20, 2021...
RAIN NOTICE: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RAIN
NEW YORK , July 28, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July...
RAIN SHAREHOLDER ALERT: Jakubowitz Law Reminds Rain Shareholders of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , July 28, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN). To receive updates on the lawsuit, fill out the form:...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of §§10(b)...
Source: https://incomestatements.info
Category: Stock Reports